دورية أكاديمية
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
| العنوان: | Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. |
|---|---|
| المؤلفون: | Mauri, Laura, Kereiakes, Dean J, Yeh, Robert W, Driscoll-Shempp, Priscilla, Cutlip, Donald E, Steg, P Gabriel, Normand, Sharon-Lise T, Braunwald, Eugene, Wiviott, Stephen D, Cohen, David J, Holmes, David R, Krucoff, Mitchell W, Hermiller, James, Dauerman, Harold L, Simon, Daniel I, Kandzari, David E, Garratt, Kirk N, Lee, David P, Pow, Thomas K, Ver Lee, Peter, Rinaldi, Michael J, Massaro, Joseph M, Windecker, Stephan |
| المصدر: | Mauri, Laura; Kereiakes, Dean J; Yeh, Robert W; Driscoll-Shempp, Priscilla; Cutlip, Donald E; Steg, P Gabriel; Normand, Sharon-Lise T; Braunwald, Eugene; Wiviott, Stephen D; Cohen, David J; Holmes, David R; Krucoff, Mitchell W; Hermiller, James; Dauerman, Harold L; Simon, Daniel I; Kandzari, David E; Garratt, Kirk N; Lee, David P; Pow, Thomas K; Ver Lee, Peter; . (2014). Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. New England journal of medicine NEJM, 371(23), pp. 2155-2166. Massachusetts Medical Society MMS 10.1056/NEJMoa1409312 |
| بيانات النشر: | Massachusetts Medical Society MMS |
| سنة النشر: | 2014 |
| المجموعة: | BORIS (Bern Open Repository and Information System, University of Bern) |
| مصطلحات موضوعية: | 610 Medicine & health |
| الوصف: | BACKGROUND Dual antiplatelet therapy is recommended after coronary stenting to prevent thrombotic complications, yet the benefits and risks of treatment beyond 1 year are uncertain. METHODS Patients were enrolled after they had undergone a coronary stent procedure in which a drug-eluting stent was placed. After 12 months of treatment with a thienopyridine drug (clopidogrel or prasugrel) and aspirin, patients were randomly assigned to continue receiving thienopyridine treatment or to receive placebo for another 18 months; all patients continued receiving aspirin. The coprimary efficacy end points were stent thrombosis and major adverse cardiovascular and cerebrovascular events (a composite of death, myocardial infarction, or stroke) during the period from 12 to 30 months. The primary safety end point was moderate or severe bleeding. RESULTS A total of 9961 patients were randomly assigned to continue thienopyridine treatment or to receive placebo. Continued treatment with thienopyridine, as compared with placebo, reduced the rates of stent thrombosis (0.4% vs. 1.4%; hazard ratio, 0.29 [95% confidence interval {CI}, 0.17 to 0.48]; P<0.001) and major adverse cardiovascular and cerebrovascular events (4.3% vs. 5.9%; hazard ratio, 0.71 [95% CI, 0.59 to 0.85]; P<0.001). The rate of myocardial infarction was lower with thienopyridine treatment than with placebo (2.1% vs. 4.1%; hazard ratio, 0.47; P<0.001). The rate of death from any cause was 2.0% in the group that continued thienopyridine therapy and 1.5% in the placebo group (hazard ratio, 1.36 [95% CI, 1.00 to 1.85]; P=0.05). The rate of moderate or severe bleeding was increased with continued thienopyridine treatment (2.5% vs. 1.6%, P=0.001). An elevated risk of stent thrombosis and myocardial infarction was observed in both groups during the 3 months after discontinuation of thienopyridine treatment. CONCLUSIONS Dual antiplatelet therapy beyond 1 year after placement of a drug-eluting stent, as compared with aspirin therapy alone, significantly reduced the ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| العلاقة: | https://boris.unibe.ch/61912Test/ |
| الإتاحة: | https://doi.org/10.1056/NEJMoa1409312Test https://boris.unibe.ch/61912/1/NEJMoa1409312.pdfTest https://boris.unibe.ch/61912Test/ |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.93233C01 |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |